PT  - JOURNAL ARTICLE
AU  - Deal, Chad L.
TI  - The HIP trial
DP  - 2002 Dec 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 964--976
VI  - 69
IP  - 12
4099  - http://www.ccjm.org/content/69/12/964.short
4100  - http://www.ccjm.org/content/69/12/964.full
SO  - Cleve Clin J Med2002 Dec 01; 69
AB  - The Hip Intervention Program (HIP) trial establishes that risedronate (Actonel) prevents hip fracture in elderly women with osteoporosis. However, the drug had no statistically significant effect on hip fracture risk in elderly women in whom bone density status was not known. Patients should be selected for bisphosphonate therapy on the basis of low bone density. A history of vertebral fractures increases the risk for hip fractures.